Immuneering Corporation (IMRX)

4d ago, source: Yahoo Finance

April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations ...

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

1mon ago, source: Zacks.com on MSN

Immuneering Corporation IMRX is a clinical-stage biotech company focused on developing universal-RAS/RAF medicines to treat ...

Immuneering Corp. Class A

1mon ago, source: CNN

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease ...

Immuneering Corp (IMRX) Shares Down Despite Recent Market Volatility

12d ago, source: newsheater

To put it simply, Immuneering Corp (IMRX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important ...

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

27d ago, source: Yahoo Finance

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for ...

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

14d ago, source:

Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic ...

Immuneering Stock (NASDAQ:IMRX), Analyst Ratings, Price Targets, Predictions

11d ago, source: Benzinga.com

$1.80 1122.22% Chardan Capital ...

Immuneering Corp Class A IMRX

11d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Immuneering Corp.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Immuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

14d ago, source: Finanznachrichten

April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of ...

Immuneering Corp Class A

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...